Join Growin Stock Community!

Ainos, inc.AIMDW.US Overview

US StockHealthcare
(No presentation for AIMDW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AIMDW AI Insights

AIMDW Overall Performance

AIMDW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AIMDW Recent Performance

-

Ainos, inc.

0.05%

Avg of Sector

-0.31%

S&P500

AIMDW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AIMDW Key Information

AIMDW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AIMDW Profile

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Price of AIMDW

AIMDW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AIMDW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
82.61%
Net Margin
-7026.55%
Revenue Growth (YoY)
226.18%
Profit Growth (YoY)
185.11%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
82.61%
Net Margin
-7026.55%
Revenue Growth (YoY)
226.18%
Profit Growth (YoY)
185.11%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-%
  • When is AIMDW's latest earnings report released?

    The most recent financial report for Ainos, inc. (AIMDW) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AIMDW's short-term business performance and financial health. For the latest updates on AIMDW's earnings releases, visit this page regularly.

  • What is the operating profit of AIMDW?

    According to the latest financial report, Ainos, inc. (AIMDW) reported an Operating Profit of -3.16M with an Operating Margin of -2,978.02% this period, representing a decline of 1.37% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is AIMDW's revenue growth?

    In the latest financial report, Ainos, inc. (AIMDW) announced revenue of 106.21K, with a Year-Over-Year growth rate of 412.36%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does AIMDW have?

    At the end of the period, Ainos, inc. (AIMDW) held Total Cash and Cash Equivalents of 1.22M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does AIMDW go with three margins increasing?

    In the latest report, Ainos, inc. (AIMDW) did not achieve the “three margins increasing” benchmark, with a gross margin of 82.83%%, operating margin of -2,978.02%%, and net margin of -3,093.98%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess AIMDW's profit trajectory and future growth potential.

  • Is AIMDW's EPS continuing to grow?

    According to the past four quarterly reports, Ainos, inc. (AIMDW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AIMDW?

    Ainos, inc. (AIMDW)'s Free Cash Flow (FCF) for the period is -1.26M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 16.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AIMDW?

    The latest valuation data shows Ainos, inc. (AIMDW) has a Price-To-Earnings (PE) ratio of -0.59 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.